A comparative study of fixed dose of Tamsulosin with finasteride vs Tamsulosin with dutasteride in the management of benign prostatic hyperplasia

被引:3
|
作者
Mohanty, N. K. [1 ]
Singh, Uday Pratap [1 ]
Sharma, Nitin K. [1 ]
Arora, R. P. [1 ]
Amitabh, Vindu [1 ]
机构
[1] VM Med Coll & Safdarjang Hosp, Dept Urol, New Delhi, India
关键词
Dutasteride; finasteride; tamsulosin;
D O I
10.4103/0970-1591.26567
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: The aim of this study was to compare the efficacy, safety and tolerability of Dutasteride vs Finasteride in a fixed dose combination, with a uro-selective a-blocker Tamsulosin, in the management of symptomatic BPH associated with LUTS. MATERIALS AND METHODS: 105 males between 40-80 years, clinically diagnosed as Benign prostatic hyperplasia (BPH) having a baseline evaluation of their IPSS, UFR, PSA, LFT, KFT, sex health, ultrasound of prostate and PVUV, were randomized to receive a fixed dose combination therapy of Tamsulosin (0.4 mg) with Finasteride (5 mg), vs Tamsulosin (0.4 mg) with Dutasteride (0.5 mg), daily for six consecutive months. Follow-up at the end of the 2nd, 4th, 8th, 12th and 24th week was done with IPSS, UFR, PSA, ultrasound of Prostate, PVUV and sex health. RESULTS: There were five dropouts, three from the Finasteride arm and two from Dutasteride arm, leaving a total of 100 patients for the final evaluation. Patients in both the groups showed improvement in their symptoms score and urine flow rate from the baseline, but those with the Dutasteride combination not only showed much better improvement in their symptoms score and urine flow, but were also relieved of their obstructive symptoms earlier (10-14 days) than seen in the Finasteride group (24-35 days). None of the patients had acute retention of urine (AUR) during the trial. The post void urine volume was decreased more in the Dutasteride group, than in patients with Finasteride. Sexual dysfunction incidence was same in both the groups. Approximately 50% reduction in the PSA level was seen in both the groups, while LFT did not show significant difference from the baseline, in either group. Both the drugs were well tolerated, with the patient's good compliance and with no drop-out due to adverse effects. CONCLUSION: A combination of a-adrenergic blocker and 5-ARI is the best therapeutic option for medical management of BPH as it is safe, effective and well tolerated. A combination of Tamsulosin with Dutasteride results in early symptomatic relief and low PVUV, than seen with the Tamsulosin with Finasteride combination.
引用
收藏
页码:130 / 134
页数:5
相关论文
共 50 条
  • [1] Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia
    Dimitropoulos, Konstantinos
    Gravas, Stavros
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (01) : 19 - 28
  • [2] Dutasteride/Tamsulosin In Benign Prostatic Hyperplasia
    Keating, Gillian M.
    [J]. DRUGS & AGING, 2012, 29 (05) : 405 - 419
  • [3] Dutasteride/Tamsulosin (Jalyn) for Benign Prostatic Hyperplasia
    Wilson, Stephen A.
    Broders, Jennie
    [J]. AMERICAN FAMILY PHYSICIAN, 2012, 85 (12) : 1194 - 1195
  • [4] Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada
    Sayani, Amyn
    Ismaila, Afisi
    Walker, Anna
    Posnett, John
    Laroche, Bruno
    Nickel, J. Curtis
    Su, Zhen
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (1-2): : E1 - E7
  • [5] Dutasteride (Avodart) with Tamsulosin (Flomax) for Benign Prostatic Hyperplasia
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2008, 50 (1296): : 79 - 80
  • [6] COMPARATIVE STUDY OF EFFICACY OF MEDICAL (TAMSULOSIN+DUTASTERIDE) WITH SURGICAL (TURP) MANAGEMENT IN BENIGN PROSTATIC HYPERPLASIA
    Naniwadekar, R. G.
    Biradar, Sangeeta
    Savsaviya, Jignesh
    Nagur, Basvaraj
    Chabara, Raunak
    Sawant, Neha
    [J]. JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2016, 5 (68): : 4861 - 4863
  • [7] DUTASTERIDE/TAMSULOSIN FIXED-DOSE COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC ENLARGEMENT
    Ismail, M.
    Hashim, H.
    [J]. DRUGS OF TODAY, 2012, 48 (01) : 17 - 24
  • [8] Development of microemulsion of tamsulosin and dutasteride for benign prostatic hyperplasia therapy
    Ciriaco, Shayara Lopes
    Santos Carvalho, Ivana Pereira
    Terceiro Neto, Jose Alves
    Lima Neto, Jose de Sousa
    Bento de Oliveira, Daniel Henrique
    Gomes Pereira Cunha, Ana Paula
    Duarte Cavalcante, Ykro Talvanis
    Casimiro da Silva, Dayane Tomaz
    da Silva, Jose Alexsandro
    Bezerra Barradas Mineiro, Ana Lys
    de Lima Chagas Moreno Fernandes, Maria Zenaide
    Menezes Carvalho, Andre Luis
    [J]. COLLOIDS AND SURFACES B-BIOINTERFACES, 2020, 185
  • [9] Dutasteride/tamsulosin: A guide to its use in benign prostatic hyperplasia
    Keating G.M.
    [J]. Drugs & Therapy Perspectives, 2013, 29 (4) : 91 - 96
  • [10] Development of microemulsion of tamsulosin and dutasteride for benign prostatic hyperplasia therapy
    Ciríaco, Shayara Lopes
    Carvalho, Ivana Pereira Santos
    Alves Terceiro Neto, José
    de Sousa Lima Neto, José
    de Oliveira, Daniel Henrique Bento
    Cunha, Ana Paula Gomes Pereira
    Cavalcante, Ykro Talvanis Duarte
    da Silva, Dayane Tomaz Casimiro
    da Silva, José Alexsandro
    Mineiro, Ana Lys Bezerra Barradas
    de Lima Chagas Moreno Fernandes, Maria Zenaide
    Carvalho, André Luis Menezes
    [J]. Colloids and Surfaces B: Biointerfaces, 2020, 185